Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28215437 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7696360 | 0.89 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1177836 | 0.88 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27465058 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL21121060 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL3727214 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL8892351 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL10839078 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL11842148 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL22017059 | 0.85 | MEN1 (0.53) | ALDH1A1MAPK1L3MBTL1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227724-A1 | STAR-SHAPED GRAFT COPOLYMERS | POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) | 2023-11-30 | — | — | WO | disclosed |
| US-20220274954-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| EP-4003975-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021013800-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| WO-2017132771-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2017-08-10 | — | — | WO | disclosed |
| US-4996296-A | Cromolyn binding protein in highly purifed form, and methods for the isolation thereof | YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) | 1991-02-26 | — | — | US | disclosed |
| US-4563448-A | PHYTOPATHOGENS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| US-4559342-A | Quinolone acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-17 | — | — | US | disclosed |
| EP-0118854-A1 | Bactericidal agent containing quinolone-carboxylic acids | BAYER AG (DE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0117474-A1 | Quinolone carboxylic acids, process for their preparation and antibacterial compositions containing them | BAYER AG (DE) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274954-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | DDC, ABAT, NPEPPS | ALDH1A1 487/4885MAPK1 2206/4885L3MBTL1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.